Exsilio Therapeutics, a new player in the field of genetic medicine, has emerged with a significant debut. The company, led by Tal Zaks, former Chief Medical Officer at Moderna, aims to revolutionize gene writing by inserting whole genes with minimal disruption to DNA. Exsilio has secured $82 million in funding and is pitching a significant advancement in genetic medicine. Additionally, the company has been backed by investments from prominent entities, including a $142 million seed round, suggesting strong confidence in its potential to innovate within the genomic medicine space.
#mRNA-based medicines allow for a software-like approach to creating new medicines. We're excited to announce our most recent investment in Exsilio Therapeutics - an approach that stands to bring forth a new pillar in genomic medicine. https://t.co/v0M1hLavuj https://t.co/wtruzNrz0C
There's a new AI for protein design startup, founded by ex-Meta scientist @alexrives, and backed with $142M seed by Lux, Amazon, and NVIDIA. Its first trick? Evolving a new glowy jellyfish protein. @AndrewE_Dunn and I break down the story for @endpts https://t.co/qXMLKlXian
$142m seed 👀 These folks can simulate 300m years of biological evolution... https://t.co/KYFu7IEhUZ
Exsilio debuts with $82M, pitching a ‘leap’ forward for genetic medicine https://t.co/ojvnKMu7q4 by @gwendolynawu $MRNA $CRSP
Tal Zaks, who at Moderna expressed skepticism of genome editing, says his new company Exsilio Therapeutics has a way to insert whole genes with minimal disruption to DNA. https://t.co/Fh7yEXmS1i
🧬 GENE WRITING: Exsilio Therapeutics RNA > DNA?? A new player emerges…. https://t.co/yn9jmmJ6Nm
🧬 GENE WRITING: Exsilio Therapeutics A new player with a legendary CEO…. https://t.co/yn9jmmJ6Nm